Pfizer and Novo Nordisk seem to want Metsera bad. Analysts are wondering, though: is the obesity biotech really worth this much effort?

Biotech company Amgen (NASDAQ:AMGN) beat Wall Street’s revenue expectations in Q3 CY2025, with sales up 12.4% year on year to ...

Clinical research company Fortrea Holdings (NASDAQ:FTRE) announced in Q3 CY2025, with sales up 3.9% year on year to $701.3 million. The company’s full-year revenue guidance of $2.73 billion at the ...

The biotechnology company posted revenue of $159.9 million in the period, also missing Street forecasts. Eight analysts surveyed by Zacks expected $167.6 million. Ultragenyx expects full-year revenue ...

On a per-share basis, the Thousand Oaks, California-based company said it had net income of $5.93. Earnings, adjusted for non-recurring gains, were $5.64 per share. The results surpassed Wall Street ...

Two scientists argue that the growing commercial efforts to counter climate change by reflecting away sunlight will thwart ...

2. Mergers and acquisitions are picking up: So far this year, buyouts have boosted several biotech stocks. Some standouts: Regulus Therapeutics went up 120%; 89bio went up 85%; Chimerix gained 69% and ...

It is a smart strategy to diversify your portfolio by investing in high-quality companies built on proven technologies.

U.S. science always suffers during government shutdowns. Funding lapses send government scientists home without pay. Federal agencies suspend new grant opportunities, place expert review panels on ...

UD chemical engineer wins the AIChE Langer Prize for efforts to harness biology to manage plastic waste sustainably ...

A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes towards the controversial approach.